An Open-Label Study of the Safety and Clinical Pharmacology of Stanate in Infants At-Risk for Exchange Transfusion

Trial Profile

An Open-Label Study of the Safety and Clinical Pharmacology of Stanate in Infants At-Risk for Exchange Transfusion

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2016

At a glance

  • Drugs Stannsoporfin (Primary)
  • Indications Hyperbilirubinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors InfaCare Pharmaceutical Corporation
  • Most Recent Events

    • 10 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top